Cite
Marshall CH, Fu W, Wang H, et al. Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2021;27(6):1623-1630doi: 10.1158/1078-0432.CCR-20-4476.
Marshall, C. H., Fu, W., Wang, H., Park, J. C., DeWeese, T. L., Tran, P. T., Song, D. Y., King, S., Afful, M., Hurrelbrink, J., Manogue, C., Cotogno, P., Moldawer, N. P., Barata, P. C., Drake, C. G., Posadas, E. M., Armstrong, A. J., Sartor, O., & Antonarakis, E. S. (2021). Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1623-1630. https://doi.org/10.1158/1078-0432.CCR-20-4476
Marshall, Catherine H, et al. "Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,6 (2021): 1623-1630. doi: https://doi.org/10.1158/1078-0432.CCR-20-4476
Marshall CH, Fu W, Wang H, Park JC, DeWeese TL, Tran PT, Song DY, King S, Afful M, Hurrelbrink J, Manogue C, Cotogno P, Moldawer NP, Barata PC, Drake CG, Posadas EM, Armstrong AJ, Sartor O, Antonarakis ES. Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2021 Mar 15;27(6):1623-1630. doi: 10.1158/1078-0432.CCR-20-4476. Epub 2021 Jan 15. PMID: 33451978; PMCID: PMC8121020.
Copy
Download .nbib